Cargando…

A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new med...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Díaz, María Belén, Viera, Sara, Ibáñez, Javier, Mulet, Teresa, Magán-Marchal, Noemí, Garuti, Helen, Gómez, Vanessa, Cortés-Gil, Lorena, Martínez, Antonio, Ferrer, Santiago, Fraile, María Teresa, Calderón, Félix, Fernández, Esther, Shultz, Leonard D., Leroy, Didier, Wilson, David M., García-Bustos, José Francisco, Gamo, Francisco Javier, Angulo-Barturen, Iñigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692522/
https://www.ncbi.nlm.nih.gov/pubmed/23825598
http://dx.doi.org/10.1371/journal.pone.0066967
_version_ 1782274632855846912
author Jiménez-Díaz, María Belén
Viera, Sara
Ibáñez, Javier
Mulet, Teresa
Magán-Marchal, Noemí
Garuti, Helen
Gómez, Vanessa
Cortés-Gil, Lorena
Martínez, Antonio
Ferrer, Santiago
Fraile, María Teresa
Calderón, Félix
Fernández, Esther
Shultz, Leonard D.
Leroy, Didier
Wilson, David M.
García-Bustos, José Francisco
Gamo, Francisco Javier
Angulo-Barturen, Iñigo
author_facet Jiménez-Díaz, María Belén
Viera, Sara
Ibáñez, Javier
Mulet, Teresa
Magán-Marchal, Noemí
Garuti, Helen
Gómez, Vanessa
Cortés-Gil, Lorena
Martínez, Antonio
Ferrer, Santiago
Fraile, María Teresa
Calderón, Félix
Fernández, Esther
Shultz, Leonard D.
Leroy, Didier
Wilson, David M.
García-Bustos, José Francisco
Gamo, Francisco Javier
Angulo-Barturen, Iñigo
author_sort Jiménez-Díaz, María Belén
collection PubMed
description The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P(0)) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task.
format Online
Article
Text
id pubmed-3692522
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36925222013-07-02 A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery Jiménez-Díaz, María Belén Viera, Sara Ibáñez, Javier Mulet, Teresa Magán-Marchal, Noemí Garuti, Helen Gómez, Vanessa Cortés-Gil, Lorena Martínez, Antonio Ferrer, Santiago Fraile, María Teresa Calderón, Félix Fernández, Esther Shultz, Leonard D. Leroy, Didier Wilson, David M. García-Bustos, José Francisco Gamo, Francisco Javier Angulo-Barturen, Iñigo PLoS One Research Article The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P(0)) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task. Public Library of Science 2013-06-25 /pmc/articles/PMC3692522/ /pubmed/23825598 http://dx.doi.org/10.1371/journal.pone.0066967 Text en © 2013 Jiménez-Díaz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jiménez-Díaz, María Belén
Viera, Sara
Ibáñez, Javier
Mulet, Teresa
Magán-Marchal, Noemí
Garuti, Helen
Gómez, Vanessa
Cortés-Gil, Lorena
Martínez, Antonio
Ferrer, Santiago
Fraile, María Teresa
Calderón, Félix
Fernández, Esther
Shultz, Leonard D.
Leroy, Didier
Wilson, David M.
García-Bustos, José Francisco
Gamo, Francisco Javier
Angulo-Barturen, Iñigo
A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title_full A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title_fullStr A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title_full_unstemmed A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title_short A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
title_sort new in vivo screening paradigm to accelerate antimalarial drug discovery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692522/
https://www.ncbi.nlm.nih.gov/pubmed/23825598
http://dx.doi.org/10.1371/journal.pone.0066967
work_keys_str_mv AT jimenezdiazmariabelen anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT vierasara anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT ibanezjavier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT muletteresa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT maganmarchalnoemi anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT garutihelen anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT gomezvanessa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT cortesgillorena anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT martinezantonio anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT ferrersantiago anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT frailemariateresa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT calderonfelix anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT fernandezesther anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT shultzleonardd anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT leroydidier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT wilsondavidm anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT garciabustosjosefrancisco anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT gamofranciscojavier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT angulobartureninigo anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT jimenezdiazmariabelen newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT vierasara newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT ibanezjavier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT muletteresa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT maganmarchalnoemi newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT garutihelen newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT gomezvanessa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT cortesgillorena newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT martinezantonio newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT ferrersantiago newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT frailemariateresa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT calderonfelix newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT fernandezesther newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT shultzleonardd newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT leroydidier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT wilsondavidm newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT garciabustosjosefrancisco newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT gamofranciscojavier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery
AT angulobartureninigo newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery